During this past year DC PFAP has made substantial progress in the following areas 1. The DC Cohort database has over 9000 patients enrolled. The program is enrolling at all sites. Data analysts are looking at merged data. This database is providing unique, real time granularity for the city HIV population. The data is meshed with the DC Department of Health database to enhance its utility for analyzing the city epidemic. Abstracts and manuscripts are in progress. 2. The prevention protocols have exceeded expectations in terms of enrolling African American men and women in studies to assess their risk behavior. Based on superior enrollment and retention of subjects, the DC investigators have been invited to participate In PREP studies have been completed with DC sites being among the leaders in enrollment and retention in follow up. 3. All studies performed are investigator-initiated studies, which recruited almost exclusively among the citys underserved populations. Studies completed in the past three years have included unique studies of various combination regimens in HIV infected and uninfected patients. The program has focused on science-based studies looking at mechanisms of action and correlates of response in tissue and in blood. This past year has witnessed the publication of studies assessing the efficacy of 4 week regimens. For most patients, such short regiemens have inadequate efficacy, but efforts are underway to identify immunologic and virologic correlates of success for short regimens. A major study on retreatment of initial treatment failures was also completed and published. This was the first study assessing the feasibility of retreatemth of HCV. Also completed was an ambitious study to determine whether primary care providers could deliver DAA therapy safely and effectively. This sudy has been presented at major meetings and has engendered a high level of interest since it suggests that the pool of providers capable of treating HCV could be much larger than subspecialists alone. This study will be submitted for publication in the fourth quarter of 2016 4. The program has established new relationships with clinics that serve clients who are sex workers, who have illegal substance use issues and who have sexually transmitted diseases. New studies entitled GRAVITY, CEASE and ANCHOR will explore methods to identify incident cases and newly recognized prevalent cases. The goal is to design a Getting to Zero strategy for the District of Columbia. This project is fulfilling all of its missions ahead of schedule. The program is working effectively with the DC Center for AIDS Research and with community and academic partners to build a strong AIDS research network in DC.

National Institute of Health (NIH)
Clinical Center (CLC)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Clinical Center
Zip Code
Emmanuel, Benjamin; Masur, Henry; Kottilil, Shyam et al. (2018) Expansion of Treatment for Hepatitis C Virus Infection. Ann Intern Med 168:457-459
Lucar, Jose; Hart, Rachel; Rayeed, Nabil et al. (2018) Sexually Transmitted Infections Among HIV-Infected Individuals in the District of Columbia and Estimated HIV Transmission Risk: Data From the DC Cohort. Open Forum Infect Dis 5:ofy017
Chaudhury, Chloe S; Sheehan, Julia; Chairez, Cheryl et al. (2017) No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV. J Infect Dis 217:47-50
Aldous, Annette M; Castel, Amanda D; Parenti, David M et al. (2017) Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014. BMC Res Notes 10:474
Levy, M E; Greenberg, A E; Hart, R et al. (2017) High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC. HIV Med 18:724-735
Wilson, Eleanor M; Kattakuzhy, Sarah; Sidharthan, Sreetha et al. (2016) Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis 62:280-8
Kattakuzhy, Sarah; Wilson, Eleanor; Sidharthan, Sreetha et al. (2016) Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis 62:440-447
Meissner, E G; Kohli, A; Virtaneva, K et al. (2016) Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat 23:496-505
Tang, L; Ward, H; Kattakuzhy, S et al. (2016) Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol 10:21-36
Castel, Amanda D; Kalmin, Mariah M; Hart, Rachel L D et al. (2016) Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC. AIDS Care 28:1355-64

Showing the most recent 10 out of 43 publications